Immuron Ltd ADR (IMRN)
Immuron Ltd ADR is a NASDAQ-listed depositary receipt representing common stock of Immuron Limited, a biopharmaceutical company based in Carlton, Australia. Through its research and development and hyper-immune products segments, the company focuses on polyclonal antibodies and related products in Australia, the United States, and Canada. Its commercial portfolio includes Travelan, an over-the-counter product used to help reduce the risk of travelers’ diarrhea and minor gastrointestinal disorders, and Protectyn, an immune supplement aimed at supporting digestive and liver health. Immuron is also advancing several development programs, including Travelan (IMM-124E) and IMM-529 in Phase II trials, as well as IMM-986 in pre-clinical development. The company has research collaborations with the US Naval Medical Research Command and the Walter Reed Army Institute of Research.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IMRN
|
$1.66
|
44.6% Upside
|
Undervalued
|
$3.92
|
241.0% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 28, 2026
|
-2.8x
|
1.0x
|
1.7x
|
9.172 M
|
2.185 M
|
1.5%
|
97.8%
|
-4.5
|
—
|
101.2%
|
